Cannabinoids (CBs) show promise as neuroprotectants with some agents already licensed in humans for other conditions. We systematically reviewed CBs in preclinical stroke to guide further experimental protocols. We selected controlled studies assessing acute administration of CBs for experimental stroke, identified through systematic searches. Data were extracted on lesion volume, outcome and quality, and analyzed using random effect models. Results are expressed as standardized mean difference (SMD) with 95% confidence intervals (CIs). In all, 144 experiments (34 publications) assessed CBs on infarct volume in 1,473 animals. Early and late neuroscores significantly improved with CB use (−1.27 (−1.58, − 0.95), P o0.00001; − 1.63 (−2.64, − 0.62), P o 0.002 respectively) and there was no effect on survival. Statistical heterogeneity and publication bias was present, median study quality was 4 (range 1 to 6/8). Overall, CBs significantly reduced infarct volume and improve functional outcome in experimental stroke. Further studies in aged, female and larger animals, with other co-morbidities are required.
INTRODUCTION
Components of the endocannabinoid system (ECS) are altered after ischemic stroke. The expression of cannabinoid (CB) 1 and CB 2 receptors is upregulated in the rat brain after cerebral ischemia, 1, 2 indicating that the ECS may have an important role in the endogenous response to stroke, though the relevance of these changes is not known. Human and animal in vivo data have shown increases in neurolonal levels of anandamide (AEA), oleoylethanolamide (OEA), and palmitoylethanolamide (PEA), with 2-arachidonoylglycerol levels either unchanged or increased. [3] [4] [5] [6] [7] [8] Preclinical stroke studies have derived neuroprotective qualities from a range of approaches to manipulate the ECS. For example, CB 2 ligands can modify the poststroke inflammatory response, and CB 1 activation can initiate a chemical hypothermia, with both processes resulting in a decrease in stroke infarct volume. 9, 10 Activation of CB 2 receptors has only showed protective effects and the role of CB 1 activation is less clear with studies demonstrating efficacy of both CB 1 agonists and antagonists. 11, 12 Cannabinoids can be divided into three categories: endocannabinoids, phytocannabinoids, and synthetic CBs. Anandamide and 2-arachidonoylglycerol (both CB 1/2 agonists) are the best-studied endocannabinoids, but other chemically similar compounds have been suggested as endocannabinoids or endocannabinoid-like compounds, including OEA, PEA, lauroylethanolamide, and linoleoylethanolamide. Endocannabinoids also display activity at non-CB 1/2 receptor sites, including TRPV1 (transient receptor potential cation channel subfamily V1), peroxisome proliferatoractivated receptor (PPAR)α/γ, 5HT 1A , and GPR55. 13 Phytocannabinoids are derived from the cannabis plant, a unique source of over 60 different compounds, with Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) already in clinical use to treat spasticity in multiple sclerosis (Sativex). Δ 9 -tetrahydrocannabinol is a partial agonist for CB 1 and CB 2 receptors, while CBD displays low affinity for CB receptors.
14 Synthetic CB compounds have been developed, some of which exhibit high potency at CB 1 (arachidonyl-2'-chloroethylamide) or CB 2 (JWH-133, O-1966 , and O-3853) receptors, activate both CB 1/2 (CP 55940, HU-210, TAK-937, and WIN 55212-2), or activate non-CB receptors (e.g., HU-211, a proposed NMDA antagonist).
Given the accumulating preclinical evidence for the use of CBs in stroke, as well as the expansion in the use of CB-based medicines in other disorders, a systematic review of the currently available preclinical literature is warranted. While it is clear that there are many studies describing the benefit of administering CBs for experimental stroke, a number of unanswered questions remain before the transition is made into 'bedside' testing. It is unclear as to whether the optimal time of administration and dose of the various CB classes have been established, and whether the body of evidence is reliable and consistent. The aim of this study, therefore, is to systematically review and meta-analyze the effects of exogenous CB administration on infarct volume, functional outcome, and survival in animal models of ischemic stroke.
MATERIALS AND METHODS

Search Criteria
Experimental (nonhuman) studies in evaluating the effect of CBs on focal acute stroke were searched up to December 2013 in PubMed, Medline, Embase, ScienceDirect, and Web Of Science. Search keywords included were 'stroke,' 'ischemia,' 'cannabinoid,' 'cannabidiol,' 'delta-9-tetrahydrocannabinoid,' 'WIN 55212-2,' '2-Arachidonoy glycerol,' 'endocannabinoids,' 'CB 1 receptors,' and 'CB 2 receptors.' References from included studies and conference proceedings were also searched. There was no protocol per se, although prespecified exclusion criteria were used to prevent bias and studies were included if the following were met: (1) a focal ischemic stroke model, not global; (2) treatment was given for an acute model (within 48 hours), not chronic; (3) only CB ligands were given; (4) there was a control group; (5) there were measures of infarct size, functional outcome, or survival; and (6) data were from an original article, not a review article. If an article was only available as an abstract, then it was not included.
Data Acquisition Data on total infarct size, measured in percentage (%) or volume (mm 3 ) were extracted from included papers. Volumes corrected for edema were chosen instead of uncorrected data. When all data were not available, authors were contacted for the exact numbers of animals used in each group for each experiment. If authors were unable to provide necessary information, then the lowest number of animals within the range given was used. The Grab application (version 1.5) was used to obtain values from figures given in published articles if no values were stated within the text. Similarly, information on vital status, weight (grams), Rotarod test (time spent on Rotarod expressed in seconds or percentage compared with baseline), and neurologic score were collected. If published articles used multiple groups (e.g., to assess time response relationships) with one control group, then the number of animals per control group was divided into the number of comparison groups. Since different procedures were used in different experiments, the total dose of drug given throughout a complete experiment was taken instead of a single dose. When drugs were given at more than one point of time, the earliest time of administration was used. Quality Methodological quality was assessed using an eight-point criteria derived from STAIR, 15 as used previously, 16, 17 with 1 point given to evidence of the following: the presence of randomization, monitoring temperature throughout the experiment, masked outcome measurement, assessment of outcome at days 1 to 3, assessment of outcome at days 7 to 30, assessment of outcome other than just infarct size, dose-response relationship conducted, and therapeutic time window relationship of a particular agonist conducted.
Data Analysis
Data were grouped before analysis by (1) model type (permanent or transient ischemia); (2) species; (3) time to treatment; (4) total dose, and (5) CB type. Data from each of these groups were analyzed as forest plots using the Cochrane Review Manager software (version 5.2, Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) and Stata (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX, USA), as used in the previous animal meta-analyses. 17 Since heterogeneity was expected between study protocols (different species, stroke models, dose, and time), random-effect models were used. The results of continuous data are expressed as standardized mean difference (SMD), with 95% confidence intervals (CIs), which allows data measured on different scales and in different species to be merged. The results of binary data (survival) are expressed as odds ratios with 95% CI. Studies were weighted by sample size and statistical significance was set at Po 0.05. PRISM 6 (GraphPad, Software, La Jolla, CA, USA) was used to compare the dose-and time-response relationship between drug classes. Infarct volume data acquired can be accessed at http://dx.doi.org/10.6084/m9. figshare.1228070.
RESULTS
Design of the Studies
The initial search for studies identified 111 relevant publications. Once the prespecified inclusion criteria were applied, a total of 34 publications were chosen for analysis ( Figure 1 ; Table 1 ). These came from 18 laboratories in 9 countries (USA, Israel, Italy, Japan, Spain, Denmark, Germany, UK, and China). Studies were excluded if they examined global ischemia, neonatal animals, did not measure infarct volume or functional outcome, did not administer a CB receptor ligand, were review articles (not original articles), where induction of injury was by methods other than ischemia/ reperfusion or if the data were unobtainable.
In all, 19 of 34 publications studied 786 rats 5,10,18-34 and 14 studied 673 mice; 3, 9, 11, 12, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] 1 article studied rats and primates. 45 Twenty-four articles examined greater than one experimental paradigm (total number of experiments 144). Transient ischemic models were used in 21 publications, with vessel occlusion time ranging between 30 minutes and 4 hours. Permanent models of ischemia were used in 13 articles (photothrombotic n = 2). Drugs were administered intravenously (n = 17) or via the peritoneum (n = 16), and one study used the oral route. 44 Time of administration ranged from preischemia up to 5 days after middle cerebral artery occlusion (MCAo). Median study quality was 4 (range 1 to 6).
Infarct Volume Overall, administration of CB receptor ligands reduced infarct volume in comparison with vehicle; SMD − 1.49, 95% CI, − 1.73 to − 1.25, P o0.00001 ( Figure 2 ; Table 2 ). If we only include the 18 publications (75 experiments, 767 animals) reporting absolute lesion volume in the analysis, then the weighted mean difference between groups was − 28.3 mm 3 (95% CI − 32.4, − 24.2, Po 0.00001) in favor of CBs; equivalent to an SMD of − 1.27 (95% CI − 1.58, − 0.97, P o 0.00001).
Infarct volume was significantly reduced in rats and mice, SMD − 1.75, (95% CI − 2.15 to − 1.35, P o0.00001) and − 1.34 (95% CI − 1.61 to − 1.06, P o0.00001), respectively. The only study involving primates revealed nonsignificant infarct volume reduction upon administration of TAK-937, a CB 1 /CB 2 receptor ligand (SMD − 0.55, 95% CI − 1.62 to 0.53, P = 0.32). 45 When grouped by drug class, synthetic agonists (mixed CB 1 /CB 2 ligands (P o 0.00001), CB 2 ligands (P o 0.00001), HU-211 (P o 0.0001)), phytocannabinoids (THC and CBD (both Po 0.00001)), and endocannabinoids (P = 0.002) all reduced infarct volume significantly (see Table 2 ). The breakdown by individual compound can be seen in Figure 2 ; the most profound infarct volume reduction is seen with HU-210, a synthetic CB 1 /CB 2 ligand (n = 8 experiments, 80 animals (SMD − 3.52, 95% CI − 5.34 to − 1.71). 10 Methanandamide, lauroylethanolamide, and linoleoylethanolamide were all neutral in their effect, whereas AEA (n = 3, 28 animals) showed borderline significant infarct volume reduction (SMD − 0.78, 95% CI − 1.64 to 0.08, P = 0.07).
Individual studies of the CB 1 antagonist SR141716 had a neutral effect on lesion volume except when used at a very high dose (20 mg/kg 11 ) leading to a significant reduction in lesion size (SMD − 5.59 [95% CI − 9.69, − 1.49], P = 0.008). Trends to harm were seen using the CB 2 antagonist SR144528 (SMD 0.96, 95% CI − 0.32 to 2.24 P = 0.14).
There was significant statistical heterogeneity (I 2 56%, Po 0.00001, Figure 2 ) in the all study analysis.
Drug Dose
The effect of drug class dose on infarct volume was analyzed to help establish whether there was a dose-response relationship with infarct volume reduction for each class of CB (Figure 3) .
The CB 1 /CB 2 agonists were significantly effective at numerous doses and showed a bimodal distribution of maximum effect with peaks at 45 mcg/kg (HU-210, SMD − 4.16, 95% CI − 7.17 to − 1.16, P = 0.007, n = 5 experiments, 50 animals) 10 and 5 mg/kg (WIN 55212-2, SMD − 6.0, 95% CI − 9.04 to − 2.95, P = 0.0001, n = 1, 13 animals, 25 Figure 3A ). Significant statistical heterogeneity was present (I 2 63%, P o 0.00001). The CB 2 ligands were tested between total doses 0.5 and 10 mg/kg with peak effect at 5 mg/kg (JWH-133 and O-1966, SMD − 2.38, 95% CI − 4.06 to − 0.71, P = 0.005, n = 5, 37 animals, Figure 3B ). 41, 42 There was no significant statistical heterogeneity. Δ 9 -Tetrahydrocannabinol significantly reduced infarct volume at two doses, 10 and 20 mg/kg (SMD − 0.95, 95% CI − 1.92 to − 0.02, P = 0.05, n = 3, 27 animals; and SMD − 2.41, 95% CI − 3.29 to − 1.53, Po 0.00001, n = 6, 59 animals, respectively; Figure 3D) . A doseresponse relationship was observed with CBD, the greatest lesion volume reduction using 6 mg/kg (SMD − 1.89, 95% CI − 2.7 to − 1.07, P o 0.00001, n = 6, 57 animals). 36, 38, 39 No effect was seen at the greater dose of 10 mg/kg (n = 1, 9 animals) ( Figure 3E ). Peak effect with administration of endocannabinoids was seen at 20 mg/kg (SMD − 4.28, 95% CI − 6.85 to − 1.71, P = 0.001, n = 2, 16 animals 24, 44 ) with significant but less potent effects seen with 30 and 40 mg/kg ( Figure 3F ). Statistical heterogeneity was evident in the endocannabinoid analysis (I 2 78%, P o0.00001) but not for THC and CBD.
Time of Administration
The CB 1 /CB 2 agonists, assessed up to 8 hours after stroke, revealed a gradual decline in effect size over time, with significant effects seen up to 4 to 5 hours after insult ( Figure 4A) . A similar pattern was seen for endocannbinoids but with loss of significant effect as soon as 2 to 3 hours after stroke ( Figure 4F ). HU-211 produced significant infarct volume reduction as late as 6 hours after ictus ( Figure 4C ). Both CBD (up to 6 hours) and THC (up to 4 hours) showed trends to infarct reduction with later administration but there were too few studies to produce significant values at these later time points ( Figures 4D and 4E) ; 17 of 23 experiments using CBD (and 11 of 13 for THC) administered the drug before stroke onset.
Functional Outcome and Survival Early neurologic outcome improved significantly when evaluated in 55 experiments (590 animals), SMD − 1.27 95% CI − 1.58 to − 0.95, P o0.00001. Late neurologic impairment was only assessed in 8 experiments (126 animals) but this still resulted in a significantly improved outcome (P = 0.002, Table 2 ). No effect was seen on survival in 7 experiments (154 animals).
Quality
In all, 10 of 34 publications used randomization in their design, 4 reported blinding of outcome assessments, 21 monitored temperature during surgery, 33 measured outcome at 1 to 3 days and 4 at 7 to 30 days, 28 measured outcomes other than lesion size, 12 assessed a time window for administration and 16 established dose-response effects.
There was no relationship between quality score and lesion volume effect size, Spearman's rho coefficient − 0.113, P = 0.18. Likewise, there were no significant differences in effect size when comparing individual components of the scale such as randomization and blinding of outcome assessment.
Publication Bias
Begg's funnel plots were visually analyzed to determine the presence or absence of publication bias. For all studies, significant bias was present (Egger's statistic P o0.001, Figure 5H) . 46 A significant bias was present in the subgroups CB 1/2 agonists (P o 0.001, Figure 5A ), CB 2 agonists (P = 0.023, Figure 5B ), HU-211 (P o 0.001, Figure 5C ), and endocannabinoids (P = 0.038, Figure 5F ).
DISCUSSION
This extensive meta-analysis has determined that CBs significantly reduce infarct volume in both transient and permanent models of ischemia, and improve both early and late functional outcome. Almost twice as many animals were studied in transient (n = 945) than in permanent (n = 519) models and greater infarct volume reductions were seen in permanent models (SMD − 1.67 versus − 1.41). HU-210, a CB 1 /CB 2 agonist, showed the greatest infarct volume reduction and the CB 1 /CB 2 agonist group was effective when administered as late as 5 hours after stroke onset. HU-211, a proposed NMDA antagonist and enantiomer of HU-210, was effective up to 6 hours after onset. The mechanisms of action responsible for the effects of CBs in the preclinical setting are multiple but not well understood or always explored within these studies. The CB 1 receptors are primarily located in the central nervous system, with activation known to decrease excessive glutamate release, 38 allied excitotoxicity, 47 and enhance cerebral blood flow. 48 Δ
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-Tetrahydrocannabinol, 36 TAK-937, 33 WIN 55212-2, 19 and HU-210 10 are protective through CB 1 -mediated hypothermia, an effect abolished by warming. The CB 2 receptors are expressed predominantly by cells of the immune system but they also display central nervous system presence, in particular, microglial cells activated during the course of inflammation express CB 2 receptors. 49 Activation of CB 2 receptors results in a decrease in the release of pro-inflammatory cytokines, neutrophil recruitment, 9, 41 and leukocyte adhesion to cerebral vessels. 43 Cannabinoid-induced neuroprotection is also likely to be mediated through other receptor targets, though the only proven sites include CB 1 , 36,38 CB 2 , 9,11,41 and 5HT 1A . 3, 39 For example, the effects of CBD are not inhibited by CB 1 , CB 2 , or TRPV1 (capsaicin receptor) antagonism, but its ability to decrease infarct volume and enhance cerebral blood flow appear to be mediated, at least in part, through 5HT 1A . 3, 39 Other mechanisms, such as antiinflammatory effects, are yet to be linked to a particular target site, and other known CB target sites of action such as TRPs and PPARs require further exploration. The endocannabinoid PEA is associated with reduced cell death, edema, and inflammation, 18 and OEA is thought to mediate its infarct-reducing effects through PPARα, as the protective effects of OEA were absent in PPARα − / − mice 40 and inhibited by a PPARα antagonist. 44 Our systematic review has highlighted many deficiencies in the existing literature that warrants further investigation. It is not apparent that CB 2 antagonists have been tested against mixed CB 1 /CB 2 ligands, which is important considering that CB 2 activation is a potential therapeutic target. Furthermore, expression of CB 2 receptors decreases in the first 3 hours after MCAo and then gradually increases by 24 hours. 11 It may, therefore, be of benefit to stimulate CB 2 at later time points; our time-to-treatment analysis only showed a trend to infarct volume reduction at 2 to 3 hours with CB 2 agonists and there were no experiments extending drug delivery beyond 3 hours. In this review, other CBs show promise with later administration causing significant infarct volume reduction, including CB 1 /CB 2 receptor agonists (up to 5 hours) and HU-211 (up to 6 hours). Cannabidiol may also be beneficial at later time points with trends to reduce infarct volume as late as 6 hours but there were too few studies to show a significant effect; in one study, animal survival was significantly increased even when CBD was administered 3 days after stroke. 35 The optimal dose of administration for each drug class also remains unclear. It was generally seen that higher doses resulted in a greater degree of infarct volume reduction. Furthermore, questions are raised with regard to the role of CB 1 antagonism; CB 1 agonists mediate their positive effects through the various mechanisms described but CB 1 antagonism with SR141716 used at a high dose (20 mg) also appeared to be beneficial (it was neutral at lower doses). The mechanisms of such an effect are not understood. If CB 1 agonism was detrimental in stroke, then the effects of the mixed CB 1 /CB 2 agonists should be less than that of the CB 2 -specific drugs, although this was not observed. It is more likely that beneficial effects of the CB 1 antagonist at high doses are off-target effects, non-CB 1 mediated responses, as previously suggested for SR141716A. 50 Further data are also required exploring the effects of CBs in stroke in animals with other comorbidities, as would occur in humans. For example, only one group have also observed the effects of CBs (TAK-937) in aged and female rats and larger species. 28, 45 Moreover, TAK-937 is the only compound that has examined coadministration with thrombolysis, 28 essential with regard to safety since some neuroprotectants can enhance the risks of recombinant tissue plasminogen activator-associated hemorrhage. 51 Hypertensive rats have been studied using HU-211 only, 26, 27, 34 but largely data are absent on the effects of CBs in animals with comorbidities relevant to stroke. 52 It is also clear that neurologic assessments of functional outcome at later time points are lacking with only 8 of 144 experiments (HU-211, CBD, and TAK-937) measuring late neuroscores. 26, 35, 45 This is important considering the outcomes in future clinical trials will be related to functional outcome and safety.
There are limited data regarding the safety of CBs in humans and none in the stroke population. Sativex, licenced for use in treating spasticity secondary to Multiple Sclerosis, containing THC and CBD in a 1:1 ratio (2.7 mg:2.5 mg per 100 μL), is generally well tolerated but commonly causes transient dizziness, depression, euphoria, gastro-intestinal upset, and altered appetite; uncommonly it is associated with palpitations, tachycardia, hallucinations, and suicidal ideation. 53 In a 14-week open label study of 339 patients, 5% discontinued Sativex secondary to treatment-related side effects. 54 The psychotropic side effects appear to be mediated through THC CB 1 stimulation and studies using CBD alone, however, indicate that it is very well tolerated; in three small studies CBD did not affect heart rate and blood pressure using a single 600 mg dose, [55] [56] [57] and in regular use for epilepsy (200 to 300 mg), no specific adverse events were reported (4 randomized studies of poor quality, total n = 48). 58 Our paper has a number of limitations affecting interpretation of results, issues that confound many meta-analyses. First, significant heterogeneity is present secondary to the variability in design of individual studies. This is accounted for, in part, by using a random-effect model of analysis. Moreover, further heterogeneity is introduced by organizing compounds into subgroups; although we have classed the drugs by mechanisms of action, it is likely that many will act on other target sites not identified and therefore statements on efficacy could be an underestimate or overestimate. Second, caution must also be taken due to the presence of significant publication bias; 59 our search strategy may have missed publications in less well-known journals; the noninclusion of some studies means that the estimated treatment effects could be inaccurate. Third, the results also depend on study quality that can also impact report precision; 10 of 34 publications used randomization in their design and only 4 reported blinding of outcome assessments. The impact of various quality items on reported efficacy has been previously assessed; 60 the presence or absence of randomization to a treatment group, blinding of drug allocation and blinding of outcome assessments were the most powerful determinants of outcome. In contrast, this review did not find any relationship between study quality and efficacy, even when individual components of quality were analyzed. However, the absence of some of the parameters in our 'quality' score does not necessarily mean that the experiment was performed to a poor standard; for example, evaluating timing of outcome assessments is simply expanding the cohort of evidence rather than improving the study quality. It may be that some studies did not report specific components such as randomization, which could explain why we found no relationship between quality and efficacy. Fourth, many publications would often use an inadequate number of animals in the control arms of the experiments involving multiple comparisons (e.g., comparing several dose arms with one control group) resulting in smaller control groups in the meta-analysis (it is important not to count the control animals more than once). Moreover, the small group sizes produce imprecise estimates of the variance and, therefore, the SMD. Standardized mean difference, and not weighted mean difference, was used to merge different scales measuring the same parameter; of 34 publications, 14 measured infarct volume as percentage and 18 used absolute volume (mm 3 ). Interpretation of SMD is less intuitive but it has allowed us to include significantly more studies within the analysis.
The failure of multiple neuroprotective agents to be translated into the clinical setting has been extensively highlighted in the literature, 15, 61 hence, evaluating preclinical data thoroughly and systematically before progressing to design human clinical trials is of great importance. Indeed, before moving novel experimental ideas into clinical trials, it is proposed that multicenter phase IIItype preclinical studies are performed (www.dcn.ed.ac.uk/multi part). There are no previous clinical trials using CBs in stroke but positive data from trials using CBs in other neurologic diseases already exist. 62 The pleiotropic effects of CBs on the ischemic penumbra and cerebral vasculature after stroke, combined with their excellent tolerability, make them promising candidates for future treatment.
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